Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate in diabetic vitrectomy
NCT06038968Phase 1Completed
- Sponsor
- Minia University
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of methotrexate in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Minia University. Primary endpoints: Assess retinal layers by optical coherence tomography and Assess functional outcomes by multifocal electroretinogram. Started Sep 2022; status: completed.
02
Drugs
methotrexate
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT06038968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038968.